Rony Dahan

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Regulatory T Cells

Immune Response

Top Venues

Cancer immunology research

Science immunology

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
Oren Barboy, Akhiad Bercovich, Hanjie Li, Yaniv Eyal-Lubling, Adam Yalin, Yuval Shapir Itai, Kathleen Abadie, Mor Zada, Eyal David, Shir Shlomi-Loubaton, Yonatan Katzenelenbogen, Diego Adhemar Jaitin, Chamutal Gur, Ido Yofe, Tali Feferman, Merav Cohen, Rony Dahan, Evan William Newell, Aviezer Lifshitz, Amos Tanay, Bjørt K Kragesteen
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols. Nature cancer (2024)
Oren Barboy, Akhiad Bercovich, Hanjie Li, Yaniv Eyal-Lubling, Adam Yalin, Yuval Shapir Itai, Kathleen Abadie, Mor Zada, Eyal David, Shir Shlomi-Loubaton, Yonatan Katzenelenbogen, Diego Adhemar Jaitin, Chamutal Gur, Ido Yofe, Tali Feferman, Merav Cohen, Rony Dahan, Evan William Newell, Aviezer Lifshitz, Amos Tanay, Bjørt K Kragesteen
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols. Nature cancer 5 (5) (2024)
Oren Barboy, Akhiad Bercovich, Hanjie Li, Yaniv Eyal-Lubling, Adam Yalin, Yuval Shapir Itai, Kathleen Abadie, Mor Zada, Eyal David, Shir Shlomi-Loubaton, Yonatan Katzenelenbogen, Diego Adhemar Jaitin, Chamutal Gur, Ido Yofe, Tali Feferman, Merav Cohen, Rony Dahan, Evan William Newell, Aviezer Lifshitz, Amos Tanay, Bjørt K Kragesteen
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols. Nature cancer 5 (5) (2024)
Noy Cohen Saban, Adam Yalin, Tomer Landsberger, Ran Salomon, Ajjai Alva, Tali Feferman, Bjørt K Kragesteen, Rony Dahan
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Science immunology 8 (81) (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Noy Cohen Saban, Adam Yalin, Tomer Landsberger, Ran Salomon, Ajjai Alva, Tali Feferman, Bjørt K Kragesteen, Rony Dahan
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Science immunology 8 (81) (2023)
Noy Cohen Saban, Adam Yalin, Tomer Landsberger, Ran Salomon, Ajjai Alva, Tali Feferman, Bjørt K Kragesteen, Rony Dahan
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Science immunology 8 (81) (2023)
Noy Cohen Saban, Adam Yalin, Tomer Landsberger, Ran Salomon, Ajjai Alva, Tali Feferman, Bjørt K Kragesteen, Rony Dahan
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Science immunology 8 (81) (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Ran Salomon, Hagar Rotem, Yonatan Katzenelenbogen, Assaf Weiner, Noy Cohen Saban, Tali Feferman, Bjørt K Kragesteen, Rony Dahan
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nature cancer 3 (3) (2022)
Changhao He, Rachana R Maniyar, Yahel Avraham, Roberta Zappasodi, Radda Rusinova, Walter Newman, Heidi Heath, Jedd D Wolchok, Rony Dahan, Taha Merghoub, Joel R Meyerson
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science advances 8 (8) (2022)
Ido Yofe, Rony Dahan, Bjørt K Kragesteen
Single-cell genomic approaches for developing the next generation of immunotherapies. Nature medicine 26 (2) (2020)